Document Page: First | Prev | Next | All | Image | This Release | Search

Subject: TRANSMITTAL OF POLICY MEMORANDA                                 

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: TRANSMITTAL OF POLICY MEMORANDA                                                                 

Document Number:          1

Folder SEQ  #:         39






                             DEPARTMENT OF THE ARMY
                           OFFICE OF THE SURGEON GENERAL
                                   5109 LEESBURG PIKE
                               FALLS CHURCH, VA 22041-3258


               REPLY TO
               ATTENTION Of

         SGPS-PSP



         MEMORANDUM FOR COL ROBERT P. BELIHAR, COMMAND SURGEON, USCENTCOM,
                          KACDILL AIR FORCE BASE, FL 33608-7001

         SUBJECT: Policy for Use of Anthrax Vaccine


         1. Purpose: To present recommended policy for use of anthrax
         vaccine.


         2. Discussion:

             a. Anthrax is a zoonotic disease caused by Bacillus
         anthracis. Man becomes infected by contact wit infected animals
         or contaminated animal products. A biowarfare attack with aero-
         solized anthrax spores would cause inhalation anthrax.

             b. An alum-precipitated preparation of purified B. anthracis
         protective antigen (PA) is an effective vaccine to significantly
         reduce the incidence of inhalation anthrax. Limited human data
         suggests that after the first 3 doses (0, 2, 4 weeks) of the
         recommended 6-dose series, protection against inhalation anthrax
         is afforded. Studies in rhesus monkeys indicate that 2 doses,
         14-16 days apart, provide good protection against inhalation
         anthrax. Protection is likely after two doses in humans, but
         there is little information.

             C. Contraindications for use are sensitivity to formalin,
         alum, benzethonium chloride and/or history of clinical anthrax.
         Reactogenicity is mild to moderate; the frequency may increase
         with successive doses. Up to 6% of recipients have experienced
         mild discomfort at the inoculation site for up to 72 hours, while
         a smaller proportion (




Document Page: 
First | 
Prev | 
Next | 
All | 
Image | 
This Release | 
Search






Document 6 f:/Week-36/BX003203/TRANSMITTAL OF POLICY MEMORANDA/transmittal of policy memoranda:11259610133727

Control Fields 17

File Room = sep96_declassified

File Cabinet = Week-36

Box ID = BX003203

Unit = OTSG

Parent Organization = HSC

Folder Title = TRANSMITTAL OF POLICY MEMORANDA

Folder Seq # = 39

Subject = TRANSMITTAL OF POLICY MEMORANDA

Document Seq # = 1

Document Date = 

Scan Date = 

Queued for Declassification = 01-JAN-1980

Short Term Referral = 01-JAN-1980

Long Term Referral = 01-JAN-1980

Permanent Referral = 01-JAN-1980

Non-Health Related Document = 01-JAN-1980

Declassified = 25-NOV-1996